The short answer is yes: the U.S. Food and Drug Administration (FDA) has cleared COVID-19 vaccines under emergency use authorization (EUA) and through formal product approval. As of the most commonly referenced timelines, the Pfizer-BioNTech, Moderna, and Johnson & Johnson (Janssen) vaccines each passed an EUA process during 2021, followed in December 2022 a major milestone in which the FDA granted full approval to a version of Pfizer’s vaccine for certain age groups, with other products following updated authorization paths. This article explains what EUA and approval mean in practice, the current vaccine products and their regulatory status, and how these designations affect public health use.
What emergency use authorization (EUA) means
An EUA allows the FDA to permit the use of unapproved medical products during a declared public health emergency when there is evidence of safety and effectiveness and the known benefits outweigh the known risks. For COVID-19 vaccines, EUAs authorized multiple mRNA and viral-vector vaccines in 2020 and 2021 to accelerate protection while data continued to accumulate. An EUA is not the same as full FDA approval; it is a temporary pathway that requires less extensive manufacturing and labeling commitments, though companies must continue to study and report on outcomes.
What full approval means for COVID-19 vaccines
Full approval, also called a Biologics License Amendment, requires more comprehensive data on safety, effectiveness, and manufacturing quality than an EUA. Under approval, the FDA reviews large-scale clinical trial data, longer-term follow-up, and detailed quality controls before granting a license that permits broader, ongoing use. For COVID-19 vaccines, approval builds on EUA findings and aims to increase public confidence by subjecting products to the same rigorous standards as other licensed vaccines, such as those for influenza or tetanus.
Key approval milestones
Through 2021 and into 2022, the FDA expanded approved uses for certain COVID-19 vaccines, including dosing adjustments and broader age ranges. These changes reflect ongoing review of emerging data, including effectiveness against emerging variants and safety monitoring.
| Vaccine | FDA Action | Primary Date(s) | What This Signified |
|---|---|---|---|
| Pfizer-BioNTech (Comirnaty) | First EUA | December 2020 | Allowed emergency use for certain ages |
| Pfizer-BioNTech (Comirnaty) | Full Approval (Biologics License) | August 2021 (ages 16+); updated approvals 2022–2023 | Formal approval for active vaccination and boosters in specified groups |
| Moderna (mRNA-1273) | First EUA | December 2020 (later expanded) | Emergency use for certain ages |
| Moderna (mRNA-1273) | Full Approval | January 2022 (ages 18+) | Formal approval for active vaccination and boosters in specified groups |
| Janssen (Ad26) | EUA | March 2021 | Emergency use; limited updates in later periods |
Current vaccine products and FDA status
As of recent years, the FDA-authorized and approved products for active vaccination in the U.S. include updated (monovalent and bivalent) formulations that target current circulating variants. The regulatory status of each product evolves as the virus changes and as manufacturers submit new data. While some products hold full approval for specific age groups, others currently operate under EUA for certain uses. CDC recommendations typically align with FDA decisions, and labeling, consent information, and product names have been updated accordingly.
How EUA and approved products are used in practice
In clinical and public health settings, EUA and approved products may be used according to the authorized schedule for age groups and risk categories. Providers rely on the most current CDC guidance, which incorporates FDA-authorized or approved products. Documentation, consent processes, and reporting protocols vary slightly between EUA and approved products but are designed to protect individual and population health. Understanding the difference helps individuals ask informed questions about which vaccine product they are receiving and why.
Reliable sources and further reading
- U.S. FDA: COVID-19 Vaccine Updates — official approvals, authorizations, and fact sheets
- CDC: Vaccine Product and Administrative Tools — schedules and recommendations aligned with FDA status
For reliable, up-to-date information, consult primary sources including the FDA and CDC, both of which provide label information, fact sheets, and guidance summaries tailored to the latest product and age-group authorizations. This approach supports transparent decision-making and accurate understanding of vaccine policies.